Biogen and Alectos Agree Over Parkinson’s Disease Drug Collaboration, Plus Unnamed Molecules

Biogen and Alectos Therapeutics have inked a licensing and collaboration agreement to develop Alectos’ lead investigational compound, AL01811, for treatment of patients with Parkinson’s disease.

Under the agreement, Biogen will pay $15 million upfront to Alectos for an exclusive global license to AL01811 and additional “unnamed backup molecules.”

Alectos is also eligible to receive $77.5 million in potential development payments and $630 million in potential commercial payments for reaching certain milestones.